SCYNEXIS, Inc. - Special Call Transcript
Good morning, and welcome to the SCYNEXIS Conference Call. (Operator Instructions) As a reminder, this conference call is being recorded.
I would now like to turn the call over to Troy Neubecker of Investor Relations. You may begin.
Good morning, and thank you for joining us as we report positive results from the second interim analysis of our ongoing Phase III open-label FURI of -- study -- FURI study of oral Ibrexafungerp as a salvage treatment for difficult-to-treat invasive fungal infections.
Joining me today are Dr. Marco Taglietti, President and Chief Executive Officer; Dr. David Angulo, Chief Medical Officer; and Eric Francois, Chief Financial Officer.
During this call, please note we will be making forward-looking statements. These statements are subject to factors, risks and uncertainties, including those that are detailed in today's presentation and our Form 10-K for the year ended December 31, 2018, as well as our subsequent SEC filings that may
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
